XH-S004 for non-cystic fibrosis bronchiectasis
Part of Lungs & breathing clinical trials.
This study tests whether an investigational tablet called XH-S004 can reduce flare-ups and improve symptoms in people with bronchiectasis (widened airways that trap mucus). It is for adults who produce phlegm daily and have had at least two worsening episodes in the last year.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 to 85 years old, with a BMI of 18 or higher
- Have been diagnosed with bronchiectasis (not caused by cystic fibrosis) and have daily phlegm production
- Had at least 2 lung flare-ups (exacerbations) in the past year
- Do not have COPD, asthma, or a current active infection
- Have not taken a DPP1 inhibitor before
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine, HSK31858, for people with non-cystic fibrosis bronchiectasis (a lung condition causing chronic cough and infections). It aims to see if the drug reduces lung flare-ups and improves symptoms.
This study tests how safe an experimental inhaled medicine (HSK31858) is for people with non-cystic fibrosis bronchiectasis, a lung condition where airways are damaged and collect mucus. You can only join if you already completed a previous HSK31858 study.
This trial tests an inhaled medication called CSL787 to see if it can help people with non-cystic fibrosis bronchiectasis (a lung condition that causes frequent infections and breathing problems). The study looks at different doses and checks how well the drug works and if it is safe.
This trial tests an inhaled drug called ensifentrine in people with bronchiectasis (damaged, widened airways in the lungs). The goal is to see if it can reduce flare-ups and improve symptoms.
This study tests a new medication called Galvokimig to see if it helps reduce lung infections and improve quality of life in adults with bronchiectasis (a condition where lung airways are damaged and fill with mucus). It is a 24 to 52 week treatment, and you will be monitored closely for safety and effectiveness.
This trial tests whether inhaling a saltwater solution (hypertonic saline) twice a day for 12 weeks can help people with bronchiectasis who have a chronic cough and have had flare-ups in the past. It aims to see if this treatment reduces mucus and improves quality of life.
Hear when a new Non-cystic Fibrosis Bronchiectasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.